ArticleFuture oncology (London, England)2025
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.
Smith Giri et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.